Leap Therapeutics ( (LPTX) ) has released its Q4 earnings. Here is a breakdown of the information Leap Therapeutics presented to its investors.
Leap Therapeutics is a biotechnology company specializing in targeted and immuno-oncology therapeutics, with a focus on developing treatments for cancer patients.
In its latest earnings report, Leap Therapeutics announced positive clinical data from its Phase 2 DeFianCe study for sirexatamab, a promising treatment for colorectal cancer, and shared financial results for the fourth quarter and full year 2024.
The company highlighted significant improvements in overall response rates and progression-free survival for patients with high DKK1 levels and those without prior anti-VEGF therapy. Financially, Leap reported a net loss of $67.6 million for 2024, a decrease from the previous year, primarily due to reduced research and development expenses. Cash and cash equivalents were reported at $47.2 million by the end of the year.
Leap Therapeutics is optimistic about advancing sirexatamab into a registrational Phase 3 trial, targeting a substantial market of colorectal cancer patients. The company is also progressing with its FL-501 program, aiming to initiate clinical trials in 2026.
Looking ahead, Leap Therapeutics is poised to explore strategic business development opportunities to further its pipeline and bring innovative cancer treatments to market.